Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147255557> ?p ?o ?g. }
- W2147255557 endingPage "621" @default.
- W2147255557 startingPage "605" @default.
- W2147255557 abstract "Background: Gastrointestinal (GI) symptoms and high dosing frequency have been cited as reasons for inadequate adherence to daily or weekly oral bisphosphonate therapy. Inadequate adherence may lead to poor therapeutic outcomes. Objective: The PRIOR study evaluated adherence to and GI tolerability of monthly therapy with oral and quarterly intravenous ibandronate in postmenopausal women with osteoporosis or osteopenia. Methods: This 12-month, multicenter, prospective, nonrandomized, open-label, noninferiority study included postmenopausal women with osteoporosis or osteopenia who had discontinued previous daily or weekly oral bisphosphonate therapy because of GI intolerance. Participants chose to receive either monthly oral ibandronate 150 mg or quarterly intravenous ibandronate 3 mg and were permitted to switch formulations once during the study. For oral treatment, adherence was assessed based on doses taken, as recorded on the case-report form; for intravenous treatment, adherence was assessed based on doses administered, as recorded by study site personnel. Participants who took ≥75% of protocol-specified doses were considered adherent. The rate of adherence to oral ibandronate was protocol defined as noninferior to that of intravenous ibandronate if the upper limit of the 2-sided 90% CI for the adjusted difference in adherence rates was >20%. At screening, participants assessed the tolerability of their previous bisphosphonate therapy using the GI Experience Survey; using the same instrument, they assessed the tolerability of ibandronate 1 month from baseline and at months 4, 7, and 10. Results: Of 543 participants in the intent-to-treat population, 147 (27.1%) chose to receive oral treatment and 396 (72.9%) chose to receive intravenous treatment. The mean age of participants was <66 years in both groups, and >90% of participants were white. A significantly greater proportion of participants who selected intravenous versus oral treatment had a primary diagnosis of osteoporosis (72.2% vs 57.1%, respectively; P < 0.001) and a history of fracture as an adult (35.6% vs 22.4%; P ≥ 0.004); significantly fewer recipients of intravenous versus oral ibandronate were currently working (29.0% vs 39.5%; P ≥ 0.021). Overall, 82.9% of participants had previously received alendronate and 44.9% had previously received risedronate. Eleven participants switched from oral to intravenous therapy and 16 switched from intravenous to oral therapy during the study. In the perprotocol population, 69.7% of participants in the oral group (101/145) and 82.9% of participants in the intravenous group (325/392) were adherent to their originally selected therapy. Adherence to oral therapy fell within the prespecified boundary for noninferiority to intravenous therapy (adjusted difference: 12.4%; 90% CI, 5.1–19.7). Mean GI tolerance scores were significantly improved from screening at all subsequent assessment times in both treatment groups (P < 0.001); >75% of participants had a ≥10% increase in GI tolerability scores from screening. Both dosing regimens were generally well tolerated. Conclusion: Self-selected monthly oral or quarterly intravenous ibandronate therapy was associated with high adherence rates among these postmenopausal women with osteoporosis or osteopenia who had previously discontinued oral bisphosphonate treatment because of GI intolerance." @default.
- W2147255557 created "2016-06-24" @default.
- W2147255557 creator A5010429279 @default.
- W2147255557 creator A5014809059 @default.
- W2147255557 creator A5016056181 @default.
- W2147255557 creator A5037555787 @default.
- W2147255557 creator A5079835179 @default.
- W2147255557 date "2008-04-01" @default.
- W2147255557 modified "2023-10-16" @default.
- W2147255557 title "Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation" @default.
- W2147255557 cites W136788916 @default.
- W2147255557 cites W1492812147 @default.
- W2147255557 cites W190001218 @default.
- W2147255557 cites W1973356978 @default.
- W2147255557 cites W1977227920 @default.
- W2147255557 cites W1983331153 @default.
- W2147255557 cites W1984207232 @default.
- W2147255557 cites W1989195985 @default.
- W2147255557 cites W1994046647 @default.
- W2147255557 cites W1998033364 @default.
- W2147255557 cites W1999700138 @default.
- W2147255557 cites W2006452622 @default.
- W2147255557 cites W2007233990 @default.
- W2147255557 cites W2025363160 @default.
- W2147255557 cites W2034238658 @default.
- W2147255557 cites W2037135054 @default.
- W2147255557 cites W2048541373 @default.
- W2147255557 cites W2062071669 @default.
- W2147255557 cites W2079904952 @default.
- W2147255557 cites W2088966087 @default.
- W2147255557 cites W2104922575 @default.
- W2147255557 cites W2109465803 @default.
- W2147255557 cites W2122028837 @default.
- W2147255557 cites W2124527463 @default.
- W2147255557 cites W2131056136 @default.
- W2147255557 cites W2144317224 @default.
- W2147255557 cites W2144721330 @default.
- W2147255557 cites W2150291618 @default.
- W2147255557 cites W2167515284 @default.
- W2147255557 cites W2171828790 @default.
- W2147255557 cites W2282110860 @default.
- W2147255557 cites W2336517627 @default.
- W2147255557 cites W2726799618 @default.
- W2147255557 doi "https://doi.org/10.1016/j.clinthera.2008.04.009" @default.
- W2147255557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18498910" @default.
- W2147255557 hasPublicationYear "2008" @default.
- W2147255557 type Work @default.
- W2147255557 sameAs 2147255557 @default.
- W2147255557 citedByCount "34" @default.
- W2147255557 countsByYear W21472555572012 @default.
- W2147255557 countsByYear W21472555572013 @default.
- W2147255557 countsByYear W21472555572014 @default.
- W2147255557 countsByYear W21472555572015 @default.
- W2147255557 countsByYear W21472555572017 @default.
- W2147255557 countsByYear W21472555572018 @default.
- W2147255557 countsByYear W21472555572019 @default.
- W2147255557 countsByYear W21472555572023 @default.
- W2147255557 crossrefType "journal-article" @default.
- W2147255557 hasAuthorship W2147255557A5010429279 @default.
- W2147255557 hasAuthorship W2147255557A5014809059 @default.
- W2147255557 hasAuthorship W2147255557A5016056181 @default.
- W2147255557 hasAuthorship W2147255557A5037555787 @default.
- W2147255557 hasAuthorship W2147255557A5079835179 @default.
- W2147255557 hasConcept C126322002 @default.
- W2147255557 hasConcept C140206745 @default.
- W2147255557 hasConcept C188816634 @default.
- W2147255557 hasConcept C197934379 @default.
- W2147255557 hasConcept C2776541429 @default.
- W2147255557 hasConcept C2776886416 @default.
- W2147255557 hasConcept C2777083390 @default.
- W2147255557 hasConcept C2777251235 @default.
- W2147255557 hasConcept C2777288759 @default.
- W2147255557 hasConcept C2778375690 @default.
- W2147255557 hasConcept C2908647359 @default.
- W2147255557 hasConcept C3013748606 @default.
- W2147255557 hasConcept C512399662 @default.
- W2147255557 hasConcept C71924100 @default.
- W2147255557 hasConcept C99454951 @default.
- W2147255557 hasConceptScore W2147255557C126322002 @default.
- W2147255557 hasConceptScore W2147255557C140206745 @default.
- W2147255557 hasConceptScore W2147255557C188816634 @default.
- W2147255557 hasConceptScore W2147255557C197934379 @default.
- W2147255557 hasConceptScore W2147255557C2776541429 @default.
- W2147255557 hasConceptScore W2147255557C2776886416 @default.
- W2147255557 hasConceptScore W2147255557C2777083390 @default.
- W2147255557 hasConceptScore W2147255557C2777251235 @default.
- W2147255557 hasConceptScore W2147255557C2777288759 @default.
- W2147255557 hasConceptScore W2147255557C2778375690 @default.
- W2147255557 hasConceptScore W2147255557C2908647359 @default.
- W2147255557 hasConceptScore W2147255557C3013748606 @default.
- W2147255557 hasConceptScore W2147255557C512399662 @default.
- W2147255557 hasConceptScore W2147255557C71924100 @default.
- W2147255557 hasConceptScore W2147255557C99454951 @default.
- W2147255557 hasIssue "4" @default.
- W2147255557 hasLocation W21472555571 @default.
- W2147255557 hasLocation W21472555572 @default.
- W2147255557 hasOpenAccess W2147255557 @default.
- W2147255557 hasPrimaryLocation W21472555571 @default.